Publicaciones
Artículos representativos

• Calvo-Barreiro L, Eixarch H, Cornejo T, Costa C, Castillo M, Mestre L, Guaza C, Martínez-Cuesta MDC, Tanoue T, Honda K, González-López JJ, Montalban X, Espejo C. Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. Neurotherapeutics. 2021 Apr 7. doi: 10.1007/s13311-021-01016-7
• Calvo-Barreiro L, Eixarch H, Ponce-Alonso M, Castillo M, Lebrón-Galán R, Mestre L, Guaza C, Clemente D, Del Campo R, Montalban X, Espejo C. A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. Cells. 2020 Apr 7;9(4):906. doi: 10.3390
• Mecha M, Yanguas-Casás N, Feliú A, Mestre L, Carrillo-Salinas FJ, Riecken K, Gomez-Nicola D, Guaza C.Involvement of Wnt7a in the role of M2c microglia in neural stem cell oligodendrogenesis. J Neuroinflammation. 2020 Mar 19;17(1):88. doi: 10.1186.
• Feliu A, Mestre L, Carrillo-Salinas FJ, Yong VW, Mecha M, Guaza C. 2-arachidonoylglycerol reduces chondroitin sulphate proteoglycan production by astrocytes and enhances oligodendrocyte differentiation under inhibitory conditions. Glia. 2020 Jun;68(6):1255-1273. doi: 10.1002
• Mestre L, Carrillo-Salinas FJ, Feliú A, Mecha M, Alonso G, Espejo C, Calvo-Barreiro L, Luque-García JL, Estevez H, Villar LM, Guaza C. How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process. Gut Microbes. 2020 Nov 9;12(1):1813532. doi: 10.1080
• Mecha M, Carrillo-Salinas FJ, Feliú A, Mestre L, Guaza C. Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review Front Cell Neurosci. 2020 Feb 19;14:34. doi: 10.3389
• Navarrete C, García-Martin A, Garrido-Rodríguez M, Mestre L, Feliú A, Guaza C, Calzado MA, Muñoz E. Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis Neurobiol Dis. 2020 Sep;143:104994. doi: 10.1016
• Mecha M, Yanguas-Casás N, Feliú A, Mestre L, Carrillo-Salinas F, Azcoitia I, Yong VW, Guaza C. The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia. Brain Behav Immun. 2019 Mar;77:110-126. doi: 10.1016
• Mestre L, Carrillo-Salinas FJ, Mecha M, Feliú A, Espejo C, Álvarez-Cermeño JC, Villar LM, Guaza C. Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis Front Immunol. 2019 Jun 14;10:1374. doi: 10.3389
• Mestre L, Carrillo-Salinas FJ, Mecha M, Feliú A, Guaza C. Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis. Biochem Pharmacol. 2018 Nov; 157:51-66. doi: 10.1016
• Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jiménez-Jiménez C, Mestre L, Feliú A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C, Muñoz E (2018). Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation 15, 64. doi: 10.1186
• Mecha M, Feliú A, Machín I, Cordero C, Carrillo-Salinas FJ, Mestre L, Hernández-Torres G, Ortega-Gutiérrez S, López-Rodríguez ML, De Castro F, Clemente D, Guaza C (2018) 2-AG limits Theiler´s virus induced acute neuroinflammation by modulating microglia and promoting MDSCs. GLIA Feb 27. doi: 10.1002;
• Feliú A, Del Río BI, Carrillo-Salinas FJ, Hernández-Torres G, Mestre L, Puente N, Ortega-Gutiérrez S, López-Rodríguez ML, Grandes P, Mecha M, Guaza C (2017). 2-arachidonoylglycerol reduces proteoglycans and enhances remyelination in a progressive model of demyelination. J Neurosci. 37(35):8385-8398. doi: 10.1523.
• Masgrau R, Guaza C, Ransohoff RM, Galea E (2017). Should We Stop Saying 'Glia' and 'Neuroinflammation'? Trends Mol Med. 23 (6):486-500. doi: 10.1016.
• Carrillo-Salinas FJ, Mestre L, Mecha M, Feliú A, Del Campo R, Villarrubia N, Espejo C, Montalbán X, Álvarez-Cermeño JC, Villar LM, Guaza C (2017). Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus. Sci Rep. 7: 44377. doi: 10.1038.
• Mecha M, Carrillo-Salinas FJ, Feliú A, Mestre L, Guaza C.(2016) Microglia activation states and cannabinoid system: Therapeutic implications. Pharmacol Ther. 166:40-55. doi: 10.1016.
• Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos R, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Jagerovic N. (2016) Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis. J Med Chem. 59(14):6753-71. doi: 10.1021.
• Lopez de Lapuente A*, Feliú A*, Ugidos N*, Mecha M, Mena J, Astobiza I, Riera J, Carrillo-Salinas F, Comabella M, Montalbán X, Alloza I, Guaza C, Vandenbroeck K. (2016). Novel insights into the multiple sclerosis gene risk ANKRD55. J Immunology 196 (11):4553-65. doi: 10.4049
• Hernangómez M, Klusáková I, Joukal M, Hradilová-Svíženská I, Guaza C, Dubový P. (2016) CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model. J Neuroinflammation 13(1):43. doi: 10.1186/s12974-016-0508-8.
• Del Rey A, Verdenhalven M, Lörwald AC, Meyer C, Hernangómez M, Randolf A, Roggero E, König AM, Heverhagen JT, Guaza C, Besedovsky HO. (2015). Brain-borne IL-1 adjusts glucoregulation and provides fuel support to astrocytes and neurons in an autocrine/paracrine manner. Mol Psychiatry 21: 1309-1320. doi: 10.1038/mp.2015.174.
• Mecha M, Feliú A, Carrillo-Salinas FJ, Rueda-Zubiaurre A, Ortega-Gutiérrez S, de Sola RG, Guaza C (2015). Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav Immun. 49: 233-45.
• Mestre L, Redondo M, Carrillo-Salinas FJ, Morales-García JA, Alonso-Gil S, Pérez-Castillo A, Gil C, Martínez A, Guaza C (2015). PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. Br J Pharmacol. 172(17):4277-90. doi: 10.1111
• Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C. (2015) A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Br J Pharmacol. 172(14):3579-95. doi: 10.1002
• Hernández-Torres G, Cipriano M, Hedén E, Björklund E, Canales Á, Zian D, Feliú A, Mecha M, Guaza C, Fowler CJ, Ortega-Gutiérrez S, López-Rodríguez ML. (2014). A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew Chem Int Ed Engl. 53(50):13765-70. doi: 10.1002
• Carrillo-Salinas FJ, Navarrete C, Mecha M, Feliú A, Collado JA, Cantarero I, Bellido ML, Muñoz E, Guaza C. (2014). A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis. PLoS One 9(4):e94733. doi: 10.1371
• Mecha M, Feliú A, Carrillo-Salinas FJ, Mestre L, Guaza C. (2013). Mobilization of progenitors in the subventricular zone to undergo oligodendrogenesis in the Theiler's virus model of multiple sclerosis: implications for remyelination at lesions sites. Exp Neurol. 250:348-52. doi: 10.1016
• Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C. (2013). Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol Dis. 59:141-50. doi: 10.1016
• Mecha M, Carrillo-Salinas FJ, Mestre L, Feliú A, Guaza C (2013) Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler’s virus. Prog Neurobiol 101, 46-64. doi: 10.1016